Clinical Trial Update: Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial of adjunctive or monotherapy rapastinel for major depressive disorder was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: TERMINATED | Results posted: 2020-07-17